Published in Lancet on March 29, 2003
An update on the self-care of heart failure index. J Cardiovasc Nurs (2009) 3.16
Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure. Circulation (2010) 2.23
Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle (2010) 2.04
Body composition and heart failure prevalence and prognosis: getting to the fat of the matter in the "obesity paradox". Mayo Clin Proc (2010) 1.75
Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. Can J Cardiol (2007) 1.70
Obesity and outcomes among patients with established atrial fibrillation. Am J Cardiol (2010) 1.50
Impaired muscle protein anabolic response to insulin and amino acids in heart failure patients: relationship with markers of immune activation. Clin Sci (Lond) (2010) 1.44
Molecular and cellular mechanisms of skeletal muscle atrophy: an update. J Cachexia Sarcopenia Muscle (2012) 1.40
The renin angiotensin system and the metabolic syndrome. Physiol Behav (2010) 1.25
High platelet count as a link between renal cachexia and cardiovascular mortality in end-stage renal disease patients. Am J Clin Nutr (2011) 1.13
Angiotensin II, oxidative stress and skeletal muscle wasting. Am J Med Sci (2011) 1.06
Growth hormone, insulin-like growth factor 1, and insulin signaling-a pharmacological target in body wasting and cachexia. J Cachexia Sarcopenia Muscle (2011) 1.06
Myostatin from the heart: local and systemic actions in cardiac failure and muscle wasting. Am J Physiol Heart Circ Physiol (2011) 1.03
Chronic kidney disease and outcomes in heart failure with preserved versus reduced ejection fraction: the Cardiovascular Research Network PRESERVE Study. Circ Cardiovasc Qual Outcomes (2013) 1.01
Angiotensin II inhibits satellite cell proliferation and prevents skeletal muscle regeneration. J Biol Chem (2013) 0.97
Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: potential therapeutic targets for cardiac cachexia. Int J Biochem Cell Biol (2013) 0.97
Leptin in anorexia and cachexia syndrome. Int J Pept (2012) 0.96
Cardiorenal syndrome: pathophysiology and potential targets for clinical management. Nat Rev Nephrol (2012) 0.95
The putative satiety hormone PYY is raised in cardiac cachexia associated with primary pulmonary hypertension. Heart (2005) 0.95
Treatment for chronic heart failure in the elderly: current practice and problems. Heart Fail Rev (2013) 0.93
Body mass index and the risk of all-cause mortality among patients with nonvalvular atrial fibrillation: a multicenter prospective observational study in China. Eur J Clin Nutr (2016) 0.88
Impact of obesity on quality of life and depression in patients with heart failure. Eur J Heart Fail (2006) 0.87
Skeletal muscle alterations in chronic heart failure: differential effects on quadriceps and diaphragm. J Cachexia Sarcopenia Muscle (2015) 0.87
Optimal management of cancer anorexia-cachexia syndrome. Cancer Manag Res (2010) 0.86
Obesity and hypertension, heart failure, and coronary heart disease-risk factor, paradox, and recommendations for weight loss. Ochsner J (2009) 0.85
Cachexia in malaria and heart failure: therapeutic considerations in clinical practice. Postgrad Med J (2004) 0.85
Mechanisms of Cachexia in Chronic Disease States. Am J Med Sci (2015) 0.84
Beta blockers and glucose metabolism in chronic heart failure: friend or foe? Clin Res Cardiol (2008) 0.83
Pro-HEART - a randomized clinical trial to test the effectiveness of a high protein diet targeting obese individuals with heart failure: rationale, design and baseline characteristics. Contemp Clin Trials (2013) 0.83
Critical appraisal of the obesity paradox in cardiovascular disease: how to manage patients with overweight in heart failure? Heart Fail Rev (2014) 0.83
Angiotensin type 2 receptor signaling in satellite cells potentiates skeletal muscle regeneration. J Biol Chem (2014) 0.82
Highly specific detection of myostatin prodomain by an immunoradiometric sandwich assay in serum of healthy individuals and patients. PLoS One (2013) 0.82
Skeletal muscle protein metabolism in human heart failure. Curr Opin Clin Nutr Metab Care (2013) 0.81
Angiotensin II Induces Skeletal Muscle Atrophy by Activating TFEB-Mediated MuRF1 Expression. Circ Res (2015) 0.81
Nutritional Risk Index predicts mortality in hospitalized advanced heart failure patients. J Heart Lung Transplant (2015) 0.81
The synergistic combined effect of anemia with high plasma levels of B-type natriuretic peptide significantly predicts an enhanced risk for major adverse cardiac events. Heart Vessels (2008) 0.81
Cardio-renal cachexia syndromes (CRCS): pathophysiological foundations of a vicious pathological circle. J Cachexia Sarcopenia Muscle (2011) 0.80
The link of unintentional weight loss to cardiac event-free survival in patients with heart failure. J Cardiovasc Nurs (2014) 0.80
Protein phosphatase 2C-alpha knockdown reduces angiotensin II-mediated skeletal muscle wasting via restoration of mitochondrial recycling and function. Skelet Muscle (2014) 0.80
Beneficial Effects of Physical Exercise on Functional Capacity and Skeletal Muscle Oxidative Stress in Rats with Aortic Stenosis-Induced Heart Failure. Oxid Med Cell Longev (2016) 0.79
Chronic heart failure and exercise intolerance: the hemodynamic paradox. Curr Cardiol Rev (2008) 0.78
Metabolic and immunologic derangements in cardiac cachexia: where to from here? Heart Fail Rev (2006) 0.78
Weight and mortality following heart failure hospitalization among diabetic patients. Am J Med (2011) 0.78
Association between inflammatory biomarkers and adiposity in obese patients with heart failure and metabolic syndrome. Exp Ther Med (2014) 0.78
Higher serum phosphorus is associated with catabolic/anabolic imbalance in heart failure. J Cachexia Sarcopenia Muscle (2015) 0.78
Relationship between bone mineral density and serum osteoprotegerin in patients with chronic heart failure. PLoS One (2012) 0.78
Malnutrition and associated factors among heart failure patients on follow up at Jimma university specialized hospital, Ethiopia. BMC Cardiovasc Disord (2015) 0.78
The Obesity Paradox and Heart Failure: A Systematic Review of a Decade of Evidence. J Obes (2016) 0.78
Muscle wasting and cachexia in heart failure: mechanisms and therapies. Nat Rev Cardiol (2017) 0.78
Aerobic Exercise and Pharmacological Therapies for Skeletal Myopathy in Heart Failure: Similarities and Differences. Oxid Med Cell Longev (2016) 0.78
Cardiac cachexia: hic et nunc. J Cachexia Sarcopenia Muscle (2016) 0.78
The quasi-parallel lives of satellite cells and atrophying muscle. Front Aging Neurosci (2015) 0.77
Pharmacological perspectives in sarcopenia: a potential role for renin-angiotensin system blockers? Clin Cases Miner Bone Metab (2015) 0.76
An Intronic Enhancer Element Regulates Angiotensin II Type 2 Receptor Expression during Satellite Cell Differentiation, and Its Activity Is Suppressed in Congestive Heart Failure. J Biol Chem (2016) 0.75
Sarcopenia in heart failure: mechanisms and therapeutic strategies. J Geriatr Cardiol (2016) 0.75
Lifestyle Modification with Diet and Exercise in Obese Patients with Heart Failure - A Pilot Study. J Obes Weight Loss Ther (2012) 0.75
Calcium glycerophosphate preserves transepithelial integrity in the Caco-2 model of intestinal transport. World J Gastroenterol (2015) 0.75
Obesity, Heart Failure, and Obesity Paradox. J Tehran Heart Cent (2017) 0.75
Report of a Joint Cancer Research UK/Medical Research Council workshop on cancer cachexia research at the Royal College of Physicians, Tuesday, 2 December 2003. Br J Cancer (2005) 0.75
THE RENIN-ANGIOTENSIN SYSTEM AND THE BIOLOGY OF SKELETAL MUSCLE: MECHANISMS OF MUSCLE WASTING IN CHRONIC DISEASE STATES. Trans Am Clin Climatol Assoc (2016) 0.75
Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME. Nat Rev Endocrinol (2017) 0.75
Obesity paradox in heart failure: a heavy matter. ESC Heart Fail (2016) 0.75
Inverse relationship of cardioankle vascular index with BMI in healthy Japanese subjects: a cross-sectional study. Vasc Health Risk Manag (2016) 0.75
Adjusting for reverse causation to estimate the effect of obesity on mortality after incident heart failure in the Atherosclerosis Risk in Communities (ARIC) study. Epidemiol Health (2016) 0.75
Review Of Obesity And Atrial Fibrillation: Exploring The Paradox. J Atr Fibrillation (2015) 0.75
Heart failure in the elderly. J Geriatr Cardiol (2016) 0.75
Cardiac anesthesia and surgery in geriatric patients: epidemiology, current surgical outcomes, and future directions. HSR Proc Intensive Care Cardiovasc Anesth (2009) 0.75
Tracking clinical status for heart failure patients using ballistocardiography and electrocardiography signal features. Conf Proc IEEE Eng Med Biol Soc (2014) 0.75
Weight Loss in Obese Patients With Heart Failure. J Am Heart Assoc (2016) 0.75
Cardiac Cachexia: Perspectives for Prevention and Treatment. Arq Bras Cardiol (2016) 0.75
Effect of a high-protein diet on development of heart failure in response to pressure overload. Appl Physiol Nutr Metab (2013) 0.75
Cardiac Resynchronization Therapy Leads to Improvements in Handgrip Strength. Cardiol Res (2016) 0.75
[Heart failure update 2010 and current ESC guidelines]. Herz (2010) 0.75
Integration of miRNA and mRNA expression profiles reveals microRNA-regulated networks during muscle wasting in cardiac cachexia. Sci Rep (2017) 0.75
The histone deacetylase SIRT6 blocks myostatin expression and development of muscle atrophy. Sci Rep (2017) 0.75
IL-15 promotes human myogenesis and mitigates the detrimental effects of TNFα on myotube development. Sci Rep (2017) 0.75
Muscle wasting in heart failure : The role of nutrition. Wien Klin Wochenschr (2016) 0.75
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med (2008) 19.76
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med (1991) 16.19
Statistical analysis of correlated data using generalized estimating equations: an orientation. Am J Epidemiol (2003) 15.06
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet (2008) 13.34
Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet (2008) 13.15
Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med (2004) 12.52
Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med (2006) 11.72
Universal definition of myocardial infarction. Circulation (2007) 11.69
Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med (2009) 11.49
Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet (2010) 11.25
Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med (2012) 10.09
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet (2003) 9.98
Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97
Effect of ramipril on the incidence of diabetes. N Engl J Med (2006) 9.69
Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93
Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet (2011) 8.49
Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med (2015) 7.83
Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med (2014) 7.54
Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA (2005) 7.35
Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet (2010) 7.08
Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA (2005) 6.81
Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med (2014) 6.65
The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation (2006) 6.58
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48
Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. JAMA (2007) 6.38
n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med (2012) 6.16
Aspirin in patients undergoing noncardiac surgery. N Engl J Med (2014) 6.10
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med (2008) 6.08
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med (2010) 6.05
Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet (2006) 5.85
Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation (2002) 5.79
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA (2006) 5.74
Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol (2006) 5.58
Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int (2011) 5.47
Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med (2009) 5.34
Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy. N Engl J Med (2015) 5.31
Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. Lancet (2008) 5.27
Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med (2006) 5.24
Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet (2009) 5.23
Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA (2013) 5.19
Stress (Takotsubo) cardiomyopathy--a novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunning. Nat Clin Pract Cardiovasc Med (2008) 4.91
Use of ramipril in preventing stroke: double blind randomised trial. BMJ (2002) 4.91
Association of urinary sodium and potassium excretion with blood pressure. N Engl J Med (2014) 4.86
Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med (2009) 4.83
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol (2007) 4.74
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med (2010) 4.73
Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA (2011) 4.68
Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. JAMA (2012) 4.58
Defining obesity cut points in a multiethnic population. Circulation (2007) 4.42
Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol (2005) 4.40
Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet (2008) 4.37
Need for expertise based randomised controlled trials. BMJ (2005) 4.34
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation (2012) 4.33
Off-pump or on-pump coronary-artery bypass grafting at 30 days. N Engl J Med (2012) 4.32
Effects of off-pump and on-pump coronary-artery bypass grafting at 1 year. N Engl J Med (2013) 4.27
Risk factors associated with myocardial infarction in Africa: the INTERHEART Africa study. Circulation (2005) 4.21
Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation (2007) 4.11
Increased metaboreceptor stimulation explains the exaggerated exercise pressor reflex seen in heart failure. J Appl Physiol (1985) (2007) 4.02
Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J (2005) 3.89
Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation (2003) 3.89
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation (2006) 3.85
The burden of cardiovascular disease in the Indian subcontinent. Indian J Med Res (2006) 3.80
Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation (2003) 3.78
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med (2007) 3.74
Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet (2005) 3.67
Validation and comparison of three formulae to estimate sodium and potassium excretion from a single morning fasting urine compared to 24-h measures in 11 countries. J Hypertens (2014) 3.66
Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J (2008) 3.64
Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J (2008) 3.52
Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet (2006) 3.43
Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: a systematic review and meta-analysis of randomized trials. Am Heart J (2008) 3.38
Newly identified events in the RE-LY trial. N Engl J Med (2010) 3.35
Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation (2002) 3.34
The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care (2014) 3.31
Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol (2010) 3.26
Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation (2006) 3.22
Dietary patterns and the risk of acute myocardial infarction in 52 countries: results of the INTERHEART study. Circulation (2008) 3.19
Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation (2003) 3.15
WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE). Bull World Health Organ (2005) 3.09
Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction. JAMA (2007) 3.09
Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J (2005) 3.09
Effects of exercise training in patients with heart failure: the Exercise Rehabilitation Trial (EXERT). Am Heart J (2002) 3.05